Lumiliximab and FCR Promising for Relapsed CLL (6/26/2008)
Researchers from M.D. Anderson Cancer Center have reported that a regimen of lumilixmab, fludarabine, cyclophosphamide, and rituximab (L-FCR) is effective for the treatment of patients with relapsed CLL. The details of this Phase I/II study were presented at the 2008 meeting of the American Society of Clinical Oncology in Chicago May 30-June 2.

Flavopiridol Has Significant Activity in Relapsed Chronic Lymphocytic Leukemia (6/25/2008)
Researchers from Ohio State University have reported that flavopiridol has “pronounded” activity in treating patients with relapsed chronic lymphocytic leukemia (CLL). The details of this study were presented at the 2008 meeting of the American Society of Clinical Oncology in Chicago May 30-June 2.

Sprycel® Effective for Patients with Newly Diagnosed CML (6/24/2008)
Researchers from the M.D. Anderson Cancer Center have reported that Sprycel® (dasatinib) produces rapid and complete cytogenetic response in patients with newly diagnosed chronic myeloid leukemia (CML). These data were presented at the 2008 meeting of the American Society of Clinical Oncology in Chicago May 30-June 2.

Tasigna® Effective for Patients with Newly Diagnosed CML (6/24/2008)
Researchers from the M.D. Anderson Cancer Center have reported that Tasigna® (nilotinib) produces rapid and complete cytogenetic response in patients with newly diagnosed chronic myeloid leukemia (CML). These data were presented at the 2008 meeting of the American Society of Clinical Oncology in Chicago May 30-June 2.

Patients with Lymphoma and CLL Are at Increased Risk of Lung Cancer (6/20/2008)
Researchers from Wayne State University have reported that patients with Hodgkins lymphoma (HL), non-Hodgkins lymphoma (NHL), and chronic lymphocytic leukemia (CLL) have a 30-300% increased risk of developing lung cancer compared with controls without these diseases. The details of this study were reported at the 2008 meeting of the American Society of Clinical Oncology in Chicago, May 30-June 2.